SUPN
Supernus Pharmaceuticals, Inc. NASDAQ Listed May 1, 2012$44.38
+1.84%
vs $43.58
Mkt Cap $2.6B
52w Low $30.83
47.0% of range
52w High $59.68
50d MA $48.07
200d MA $48.99
P/E (TTM)
-65.3x
EV/EBITDA
53.6x
P/B
2.4x
Debt/Equity
0.0x
ROE
-3.6%
P/FCF
54.5x
RSI (14)
38.90
ATR (14)
$1.43
Beta
0.73
50d MA
$48.07
200d MA
$48.99
Avg Volume
641.6K
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
9715 Key West Avenue · Rockville, MD 20850 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.28 | 0.60 | +115.0% | 49.19 | +3.0% | +4.6% | +1.6% | -1.4% | -4.2% | +2.3% | — |
| Feb 24, 2026 | AMC | 0.28 | 0.92 | +228.6% | 53.30 | +6.0% | +5.7% | -1.0% | -1.8% | +0.7% | -1.0% | — |
| Nov 4, 2025 | AMC | 0.82 | 1.01 | +23.2% | 57.00 | -21.6% | -17.4% | +0.3% | -2.6% | -1.3% | +1.6% | — |
| Aug 5, 2025 | AMC | 0.47 | 0.91 | +93.6% | 37.53 | +4.3% | +13.1% | -2.3% | -0.6% | -1.6% | +1.7% | — |
| May 6, 2025 | AMC | 0.38 | 0.42 | +10.5% | 32.43 | -7.4% | -4.6% | +1.9% | +0.5% | +1.4% | +0.4% | — |
| Feb 25, 2025 | AMC | 0.46 | 0.75 | +63.0% | 32.81 | +2.4% | -2.7% | -0.5% | +0.9% | -1.0% | -0.3% | — |
| Nov 4, 2024 | AMC | 0.39 | 1.06 | +171.8% | 34.70 | +13.5% | +0.1% | +8.7% | -3.6% | +0.5% | +0.0% | — |
| Aug 6, 2024 | AMC | 0.31 | 0.36 | +16.1% | 27.88 | +10.7% | +14.5% | -1.4% | +2.0% | +0.9% | +3.9% | — |
| May 8, 2024 | AMC | 0.38 | 0.26 | -31.6% | 31.30 | +0.7% | -4.2% | -3.5% | +2.5% | -2.4% | -0.8% | — |
| Feb 27, 2024 | AMC | 0.41 | 0.02 | -95.1% | 30.69 | -6.9% | +1.3% | -4.4% | +4.4% | -1.2% | -0.9% | — |
| Nov 8, 2023 | AMC | 0.13 | -0.29 | -323.1% | 23.52 | +6.3% | +11.1% | +2.0% | +2.6% | +2.6% | +2.0% | — |
| Aug 8, 2023 | AMC | 0.23 | -0.02 | -108.7% | 32.91 | -1.2% | -7.2% | +4.1% | +0.3% | -1.6% | +1.5% | — |
| May 9, 2023 | AMC | 0.17 | 0.29 | +70.6% | 36.18 | +2.3% | +1.5% | -2.2% | -4.9% | +1.8% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 | Stifel | Maintains | Hold → Hold | — | $49.28 | $48.90 | -0.8% | +4.5% | +0.0% | +0.4% | +0.1% | -0.4% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $50.67 | $51.07 | +0.8% | +2.7% | +1.6% | -0.2% | +0.9% | +4.7% |
| Oct 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $48.00 | $51.08 | +6.4% | +3.1% | -1.0% | -1.3% | +1.7% | +0.1% |
| Sep 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.60 | $48.01 | +0.9% | +0.4% | +0.5% | -0.2% | +0.8% | -0.1% |
| Aug 29 | Piper Sandler | Maintains | Neutral → Neutral | — | $45.37 | $45.58 | +0.5% | -0.6% | -1.3% | +0.9% | +1.1% | +1.3% |
| Aug 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.53 | $39.15 | +4.3% | +13.1% | -2.3% | -0.6% | -1.6% | +1.7% |
| Feb 26 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $32.81 | $33.59 | +2.4% | -2.7% | -0.5% | +0.9% | -1.0% | -0.3% |
| Feb 19 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $39.75 | $32.72 | -17.7% | -15.7% | +3.2% | -4.5% | -1.1% | +0.4% |
| Sep 11 | Piper Sandler | Downgrade | Overweight → Neutral | — | $33.49 | $32.71 | -2.3% | -7.2% | -0.6% | +0.7% | +1.2% | +0.8% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.69 | $28.58 | -6.9% | +1.3% | -4.4% | +4.4% | -1.2% | -0.9% |
| Nov 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.52 | $25.00 | +6.3% | +11.1% | +2.0% | +2.6% | +2.6% | +2.0% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $24.00 | $23.69 | -1.3% | -3.1% | -2.3% | +3.7% | +0.3% | +1.0% |
| May 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.18 | $37.00 | +2.3% | +1.5% | -2.2% | -4.9% | +1.8% | +1.2% |
| Jan 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $40.31 | $40.70 | +1.0% | +2.2% | +0.6% | -0.9% | +0.0% | -0.9% |
| Aug 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.50 | $34.15 | +1.9% | +2.2% | +2.4% | -1.9% | -0.8% | +0.3% |
| Apr 13 | Jefferies | Upgrade | Hold → Buy | — | $27.97 | $29.81 | +6.6% | +11.9% | +1.9% | -0.1% | -0.5% | -2.4% |
| Jun 16 | Piper Sandler | Upgrade | Neutral → Overweight | — | $23.07 | $24.75 | +7.3% | +6.5% | -2.4% | -0.4% | -0.6% | +0.7% |
| Apr 16 | Stifel | Maintains | Hold → Hold | — | $18.86 | $18.86 | +0.0% | -0.8% | +6.3% | -11.2% | +3.5% | -0.8% |
| Nov 7 | Stifel | Downgrade | Buy → Hold | — | $19.93 | $20.00 | +0.4% | +6.1% | +2.7% | +0.6% | -1.0% | +1.2% |
| Nov 6 | Jefferies | Downgrade | Buy → Hold | — | $29.13 | $21.96 | -24.6% | -31.6% | +6.1% | +2.7% | +0.6% | -1.0% |
| Dec 17 | Mizuho | Maintains | Buy → Buy | — | $35.76 | $36.00 | +0.7% | +0.2% | -2.3% | -4.7% | -1.5% | -5.6% |
| Nov 12 | B. Riley FBR | Maintains | Buy → Buy | — | $45.27 | $44.93 | -0.8% | -1.3% | +0.9% | -4.5% | +0.1% | +1.9% |
| Nov 12 | B. Riley Securities | Maintains | Buy → Buy | — | $45.27 | $44.93 | -0.8% | -1.3% | +0.9% | -4.5% | +0.1% | +1.9% |
| Aug 9 | Jefferies | Maintains | Buy → Buy | — | $48.70 | $48.65 | -0.1% | -1.2% | -4.1% | -5.7% | -1.8% | +1.3% |
| May 25 | Stifel | Maintains | Buy → Buy | — | $55.65 | $56.00 | +0.6% | +2.9% | -2.1% | +2.3% | -1.7% | +2.4% |
| May 5 | B. Riley FBR | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 4 | Janney Capital | Upgrade | Neutral → Buy | — | $37.20 | $38.85 | +4.4% | -0.1% | -0.1% | -1.8% | +3.0% | +1.6% |
| Dec 4 | Janney Montgomery Scott | Upgrade | Neutral → Buy | — | $37.20 | $38.85 | +4.4% | -0.1% | -0.1% | -1.8% | +3.0% | +1.6% |
| Nov 8 | B. Riley FBR | Maintains | Buy → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Nov 8 | B. Riley Securities | Maintains | Buy → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Nov 8 | Stifel | Upgrade | Hold → Buy | — | $36.40 | $37.80 | +3.8% | +1.4% | -0.9% | +1.9% | +1.5% | -1.6% |
| Sep 19 | Stifel | Downgrade | Buy → Hold | — | $49.65 | $44.70 | -10.0% | -23.4% | -3.4% | +7.2% | -1.0% | +0.3% |
| Jul 17 | Piper Sandler | Downgrade | Overweight → Neutral | — | $44.25 | $42.80 | -3.3% | -5.2% | +2.6% | +1.2% | -2.9% | -0.2% |
| Jun 1 | Piper Sandler | Upgrade | Neutral → Overweight | — | $37.60 | $38.40 | +2.1% | +3.1% | +3.4% | -2.5% | +1.5% | +2.0% |
| Aug 4 | Jefferies | Maintains | Buy → Buy | — | $22.92 | $23.44 | +2.3% | -2.6% | +3.5% | +0.4% | -0.1% | -1.9% |
| Jul 18 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| Jul 18 | Northland Securities | Downgrade | Outperform → Market Perform | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| Jul 18 | Piper Sandler | Downgrade | Overweight → Neutral | — | $21.84 | $20.27 | -7.2% | -4.9% | +0.9% | -1.4% | +1.7% | +0.1% |
| May 12 | Jefferies | Maintains | Buy → Buy | — | $16.18 | $16.34 | +1.0% | +0.6% | +6.2% | +2.3% | +0.5% | -1.9% |
| Feb 8 | Jefferies | Upgrade | Hold → Buy | — | $12.13 | $12.24 | +0.9% | +3.4% | -3.3% | +2.9% | -1.0% | +3.9% |
| Jun 18 | Jefferies | Upgrade | Hold → Buy | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
| Jun 18 | Stifel | Maintains | Buy → Buy | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
| Jun 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.01 | $16.47 | +2.9% | +6.7% | -2.9% | +1.0% | -0.1% | +0.8% |
| Mar 12 | Jefferies | Maintains | Hold → Hold | — | $11.00 | $11.22 | +2.0% | +3.7% | +3.2% | -5.1% | -0.8% | +1.1% |
| Mar 14 | Stifel | Maintains | Buy → Buy | — | $9.76 | $9.91 | +1.5% | +3.2% | -1.7% | +1.1% | -2.7% | -1.3% |
| May 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.12 | $5.20 | +1.6% | +5.3% | +1.7% | +6.6% | +2.7% | +4.3% |
| Mar 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.90 | $6.81 | -1.3% | -19.7% | -9.7% | -0.2% | +10.2% | +0.9% |
| Aug 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.48 | $12.25 | -1.8% | +6.0% | -5.7% | +2.8% | -2.5% | -1.0% |
No insider trades available.
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report Q1 2026 earnings on May 5, 2026, with management hosting a conference call at 4:30 p.m. ET for investor updates.
Apr 22
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
SUPN completed a significant asset acquisition, potentially expanding its product portfolio or market reach and signaling management confidence in growth opportunities that could drive future revenue.
Apr 7
8-K · 5.02
!!! Very High
Supernus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Supernus Pharmaceuticals modified executive compensation packages approved by its board, likely affecting future operating costs and management incentive alignment for investors tracking operational expenses.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it contains only standard boilerplate forward-looking statement disclaimers without disclosing any specific business event, transaction, or material development affecting Supernus Pharmaceuticals investors.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report its 2025 financial results on February 24, 2026, followed by a management conference call at 4:30 p.m. ET.
Feb 12
8-K · 5.02
!!! Very High
Mitek Systems, Inc. -- 8-K 5.02: Executive Change
Mitek Systems appointed Eric Bell as Chief Accounting Officer, strengthening its accounting leadership team and potentially improving financial reporting oversight for investors.
Feb 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Millennium Management | 3,315,973 | $171M | Added | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 3,238,693 | $167M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,467,215 | $128M | New | Mar 2026 |
| 4 | Morgan Stanley | 2,158,942 | $107M | Added | Dec 2025 |
| 5 | Renaissance Technologies Llc | 1,705,222 | $88M | Reduced | Mar 2026 |
| 6 | Citadel Advisors Llc | 1,493,446 | $77M | Added | Mar 2026 |
| 7 | Point72 Asset Management | 1,318,555 | $68M | Reduced | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 714,226 | $37M | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 699,456 | $36M | Added | Mar 2026 |
| 10 | D.e. Shaw & Co | 622,450 | $32M | Reduced | Mar 2026 |
| 11 | Assenagon Asset Management S.a. | 530,618 | $27M | New | Mar 2026 |
| 12 | Victory Capital Management Inc | 502,406 | $26M | Reduced | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 498,198 | $26M | Added | Mar 2026 |
| 14 | Pictet Asset Management Holding Sa | 483,399 | $25M | Reduced | Dec 2025 |
| 15 | Rice Hall James & Associates, Llc | 467,886 | $23M | Reduced | Dec 2025 |
| 16 | Woodline Partners Lp | 448,996 | $23M | New | Mar 2026 |
| 17 | Invesco Ltd. | 412,683 | $21M | Added | Mar 2026 |
| 18 | Sg Americas Securities, Llc | 377,213 | $19M | Added | Mar 2026 |
| 19 | Systematic Financial Management Lp | 376,079 | $19M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 362,408 | $19M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.58B
Enterprise Value
$2.20B
P/E (TTM)
-65.26x
Forward P/E
20.48x
PEG Ratio
0.48x
P/B
2.36x
P/S
3.48x
P/FCF
54.47x
EV/EBITDA
53.57x
Shares Out
56.5M
Financials (TTM)
Revenue
$719.0M
Net Income
-$38.5M
EBITDA
$41.0M
Free Cash Flow
$46.0M
Op Cash Flow
$47.3M
EPS Basic
$-0.68
EPS Diluted
$-0.68
EPS Forward
$2.17
Gross Margin
89.6%
Op Margin
-5.1%
Net Margin
-5.4%
Balance Sheet
Total Assets
$1.45B
Total Liab.
$390.9M
Total Equity
$1.06B
Cash
$308.7M
LT Debt
$0
Book Value/Sh
$18.81
Debt/Equity
0.04x
Current Ratio
1.90
Quick Ratio
1.66
Returns & Growth
ROE
-3.6%
ROA
-2.6%
ROIC
-2.6%
Rev Growth YoY
+8.6%
EPS Growth YoY
-150.8%
Price Returns
2W
-9.8%
1M
-3.8%
3M
-15.6%
6M
+1.3%
12M
+45.7%
Technicals
52W High
$59.68
52W Low
$30.83
50d MA
$48.07
200d MA
$48.99
RSI (14)
38.90
ATR (14)
$1.43
Beta
0.73
Avg Volume
642K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$60.00
High
$65.00
Low
$55.00
Median
$60.00
Data updated apr 27, 2026 3:34am
· Source: financialmodelingprep.com